Viatris Inc.

VTRSsupplier

Viatris is a global pharmaceutical company formed from the 2020 merger of Mylan and Pfizer's Upjohn division, focused on expanding access to generic and biosimilar medicines worldwide.

⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($15.0B)

Static data (loading live financials…)

Developed Markets (45%)

Emerging Markets (30%)

Greater China (12%)

JANZ (Japan, Australia, NZ) (13%)

Segment Breakdown & Key Customers

Product Details

Branded Generics35%

Off-patent branded drugs sold primarily in emerging markets

Complex Generics & Biosimilars25%

Biosimilar versions of Humira, Herceptin, and complex injectables

Generic Pharmaceuticals25%

Standard generic drugs for developed markets

Legacy Brands (Lipitor, EpiPen)15%

Heritage branded products from Pfizer Upjohn and Mylan

Supply Chain Relationships

Partners

Pfizer Inc.

Legacy Pfizer Upjohn product portfolio

Impact: Medium — spun off from Pfizer

Competitors

AbbVie Inc.

Biosimilar Humira competition

Impact: Medium — biosimilar erosion of Humira

Key Customers

Walgreens Boots Alliance

Generic drug retail distribution

Impact: Medium — pharmacy channel

Macro & Market Context

제약 / 바이오Sector News

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Upcoming Catalysts

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of Viatris Inc..

Company Info

Headquarters

Canonsburg, Pennsylvania, USA

Founded

2020

Employees

37,000+

Website

viatris.com

Sector Overview — 제약 / 바이오

Sector News